SLC13A3 variants cause acute reversible leukoencephalopathy and α‐ketoglutarate accumulation
- 11 January 2019
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 85 (3) , 385-395
Abstract
Objective: SLC13A3 encodes the plasma membrane Na+/dicarboxylate cotransporter 3, which imports inside the cell 4 to 6 carbon dicarboxylates as well as N‐acetylaspartate (NAA). SLC13A3 is mainly expressed in kidney, in astrocytes, and in the choroid plexus. We describe two unrelated patients presenting with acute, reversible (and recurrent in one) neurological deterioration during a febrile illness. Both patients exhibited a reversible leukoencephalopathy and a urinary excretion of α‐ketoglutarate (αKG) that was markedly increased and persisted over time. In one patient, increased concentrations of cerebrospinal fluid NAA and dicarboxylates (including αKG) were observed. Extensive workup was unsuccessful, and a genetic cause was suspected.Methods: Whole exome sequencing (WES) was performed. Our teams were connected through GeneMatcher.Results: WES analysis revealed variants in SLC13A3. A homozygous missense mutation (p.Ala254Asp) was found in the first patient. The second patient was heterozygous for another missense mutation (p.Gly548Ser) and an intronic mutation affecting splicing as demonstrated by reverse transcriptase polymerase chain reaction performed in muscle tissue (c.1016 + 3A > G). Mutations and segregation were confirmed by Sanger sequencing. Functional studies performed on HEK293T cells transiently transfected with wild‐type and mutant SLC13A3 indicated that the missense mutations caused a marked reduction in the capacity to transport αKG, succinate, and NAA.Interpretation: SLC13A3 deficiency causes acute and reversible leukoencephalopathy with marked accumulation of αKG. Urine organic acids (especially αKG and NAA) and SLC13A3 mutations should be screened in patients presenting with unexplained reversible leukoencephalopathy, for which SLC13A3 deficiency is a novel differential diagnosis. ANN NEUROL 2019;85:385–395.Keywords
Funding Information
- Association Européenne contre les Leucodystrophies (ELA 2009‐007I4)
- Fonds De La Recherche Scientifique - FNRS
- National Institutes of Health (R01 GM108911)
- Association Européenne contre les Leucodystrophies
- Fonds De La Recherche Scientifique - FNRS
This publication has 36 references indexed in Scilit:
- Drug transport by Organic Anion Transporters (OATs)Pharmacology & Therapeutics, 2012
- Extensive aspartoacylase expression in the rat central nervous systemGlia, 2011
- Molecular identification of aspartate N-acetyltransferase and its mutation in hypoacetylaspartiaBiochemical Journal, 2009
- Functional and molecular identification of sodium‐coupled dicarboxylate transporters in rat primary cultured cerebrocortical astrocytes and neuronsJournal of Neurochemistry, 2006
- Transport characteristics of N‐acetyl‐l‐aspartate in rat astrocytes: involvement of sodium‐coupled high‐affinity carboxylate transporter NaC3/NaDC3‐mediated transport systemJournal of Neurochemistry, 2005
- Substrate specificity of the human renal sodium dicarboxylate cotransporter, hNaDC-3, under voltage-clamp conditionsAmerican Journal of Physiology-Renal Physiology, 2005
- Transport of N-acetylaspartate via murine sodium/dicarboxylate cotransporter NaDC3 and expression of this transporter and aspartoacylase II in ocular tissues in mouseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2004
- Stable isotope dilution analysis ofN‐acetylaspartic acid in CSF, blood, urine and amniotic fluid: Accurate postnatal diagnosis and the potential for prenatal diagnosis of canavan diseaseJournal of Inherited Metabolic Disease, 1990
- Aspartoacylase deficiency and N‐acetylaspartic aciduria in patients with canavan diseaseAmerican Journal of Medical Genetics, 1988
- Specificity of the transport system for tricarboxylic acid cycle intermediates in renal brush bordersThe Journal of Membrane Biology, 1980